In the published article, there was an error in affiliation 3, 4, 5. Instead of “3 Reproductive Immunology Research Center, Avicenna Research Institute (ARI), Tehran, Iran, 4 Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium, 5 Breast Cancer Research Center, Motamed Cancer Institute, Tehran, Iran”, it should be “3 Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran, 4 Reproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran, 5 Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
cancer, cancer stem cells, drug designing, metabolic processes, molecular docking
Citation
Arjmand B, Kokabi Hamidpour S, Alavi-Moghadam S, Yavari H, Shahbazbadr A, Rezaei-Tavirani M, Gilany K and Larijani B (2022) Corrigendum: Molecular Docking as a Therapeutic Approach for Targeting Cancer Stem Cell Metabolic Processes. Front. Pharmacol. 13:892656. doi: 10.3389/fphar.2022.892656
Received
09 March 2022
Accepted
06 April 2022
Published
02 May 2022
Volume
13 - 2022
Edited and reviewed by
Linsheng Liu, The First Affiliated Hospital of Soochow University, China
Updates
Copyright
© 2022 Arjmand, Kokabi Hamidpour, Alavi-Moghadam, Yavari, Shahbazbadr, Rezaei-Tavirani, Gilany and Larijani.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Babak Arjmand, barjmand@sina.tums.ac.ir; Bagher Larijani, emrc@tums.ac.ir
This article was submitted to Translational Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.